GoodRx (NASDAQ:GDRX) Price Target Lowered to $6.00 at KeyCorp

GoodRx (NASDAQ:GDRX - Free Report) had its price objective lowered by KeyCorp from $7.00 to $6.00 in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Other equities analysts also recently issued research reports about the stock. Morgan Stanley cut their price target on shares of GoodRx from $7.00 to $6.00 and set an "equal weight" rating for the company in a report on Tuesday, December 17th. Barclays reduced their price target on shares of GoodRx from $10.00 to $6.00 and set an "overweight" rating for the company in a research report on Monday, November 11th. Citigroup lowered their price target on GoodRx from $10.00 to $7.00 and set a "buy" rating on the stock in a report on Wednesday, November 13th. Finally, Mizuho assumed coverage on GoodRx in a report on Wednesday, December 4th. They set a "neutral" rating and a $5.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $8.43.

GoodRx Price Performance

Shares of GoodRx stock traded down $0.13 during trading on Wednesday, reaching $4.28. The company's stock had a trading volume of 710,565 shares, compared to its average volume of 1,230,093. The business has a 50 day moving average price of $4.79 and a 200-day moving average price of $6.61. The company has a market capitalization of $1.63 billion, a P/E ratio of -142.67, a price-to-earnings-growth ratio of 3.43 and a beta of 1.27. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx has a 12-month low of $4.09 and a 12-month high of $9.26.

Institutional Trading of GoodRx

A number of hedge funds have recently bought and sold shares of the company. Rubric Capital Management LP boosted its holdings in shares of GoodRx by 25.2% during the third quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company's stock worth $32,479,000 after purchasing an additional 943,226 shares during the last quarter. Millennium Management LLC lifted its position in GoodRx by 36.5% during the second quarter. Millennium Management LLC now owns 4,121,939 shares of the company's stock worth $32,151,000 after buying an additional 1,102,758 shares during the period. American Century Companies Inc. acquired a new stake in GoodRx in the 2nd quarter worth about $18,183,000. Point72 Asset Management L.P. acquired a new stake in GoodRx in the 3rd quarter worth about $11,295,000. Finally, Geode Capital Management LLC grew its holdings in GoodRx by 6.3% in the 3rd quarter. Geode Capital Management LLC now owns 982,729 shares of the company's stock valued at $6,823,000 after buying an additional 58,610 shares during the period. Institutional investors and hedge funds own 63.77% of the company's stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.